Search Results
Search for other papers by E Patterson in
Google Scholar
PubMed
Search for other papers by R Webb in
Google Scholar
PubMed
Search for other papers by A Weisbrod in
Google Scholar
PubMed
Search for other papers by B Bian in
Google Scholar
PubMed
Search for other papers by M He in
Google Scholar
PubMed
Search for other papers by L Zhang in
Google Scholar
PubMed
Search for other papers by A K Holloway in
Google Scholar
PubMed
Search for other papers by R Krishna in
Google Scholar
PubMed
Search for other papers by N Nilubol in
Google Scholar
PubMed
Search for other papers by K Pacak in
Google Scholar
PubMed
Search for other papers by E Kebebew in
Google Scholar
PubMed
( Zarnegar et al . 2006 ). The prevalence of malignant pheochromocytoma is 2.5–40%, and the overall survival rate is <50% at 5 years ( Zarnegar et al . 2006 ). Currently, there are no reliable histologic or molecular markers for distinguishing between
Department of Pathology, Servicio de Endocrinología, Department of Medicine, University Health Network and the Ontario Cancer Institute, 200 Elizabeth Street, 11th Floor, Toronto, Ontario, Canada M5G 2C4
Search for other papers by Sonia Cheng in
Google Scholar
PubMed
Search for other papers by Wei Liu in
Google Scholar
PubMed
Search for other papers by Moises Mercado in
Google Scholar
PubMed
Search for other papers by Shereen Ezzat in
Google Scholar
PubMed
Search for other papers by Sylvia L Asa in
Google Scholar
PubMed
human liver diseases: utility as molecular markers for hepatocellular carcinoma . Journal of Hepatology 32 612 – 617 . Kondo T Ezzat S Asa SL 2006 Pathogenetic mechanisms in thyroid follicular-cell neoplasia . Nature Reviews. Cancer 6
Search for other papers by B Wängberg in
Google Scholar
PubMed
Search for other papers by A Khorram-Manesh in
Google Scholar
PubMed
Search for other papers by S Jansson in
Google Scholar
PubMed
Search for other papers by B Nilsson in
Google Scholar
PubMed
Search for other papers by O Nilsson in
Google Scholar
PubMed
Search for other papers by C E Jakobsson in
Google Scholar
PubMed
Search for other papers by S Lindstedt in
Google Scholar
PubMed
Search for other papers by A Odén in
Google Scholar
PubMed
Search for other papers by H Ahlman in
Google Scholar
PubMed
ACC is an aggressive tumour disease with clinical course that can be difficult to predict also in patients with radically resected low-stage tumours ( Vassilopoulou-Sellin & Schultz 2001 ). Besides tumour staging and Weiss score, several molecular
Search for other papers by Sofia K Gruvberger-Saal in
Google Scholar
PubMed
Search for other papers by Heather E Cunliffe in
Google Scholar
PubMed
Search for other papers by Kristen M Carr in
Google Scholar
PubMed
Search for other papers by Ingrid A Hedenfalk in
Google Scholar
PubMed
, prognosis, and treatment sensitivity, as well as traditional histopathological parameters. This review will focus on how the application of microarray-based technologies in the investigations of molecular markers has evolved from descriptive biological
Maimonides Institute for Biomedical Research of Cordoba (IMIBIC); Reina Sofia University Hospital, Córdoba, Spain
Search for other papers by Aura D Herrera-Martínez in
Google Scholar
PubMed
Search for other papers by Leo J Hofland in
Google Scholar
PubMed
Search for other papers by María A Gálvez Moreno in
Google Scholar
PubMed
Search for other papers by Justo P Castaño in
Google Scholar
PubMed
Search for other papers by Wouter W de Herder in
Google Scholar
PubMed
Search for other papers by Richard A Feelders in
Google Scholar
PubMed
effect of the mTOR inhibitor everolimus and red arrows the effect of the tyrosine kinase inhibitor sunitinib. Molecular markers are presented in blue. Response to sunitinib has been related to decreased SDF1, IL-8, VEGFR 2-3, CD14 monocytes expressing
Search for other papers by M Niedziela in
Google Scholar
PubMed
’ of thyroiditis ( Loh et al. 1999 ). The question arises as to whether the thyroiditis preceded the nodule or vice versa. New data coming from molecular studies of the BRAF mutations, the molecular marker of PTC, indicate that the
Search for other papers by Robert C Smallridge in
Google Scholar
PubMed
Search for other papers by Laura A Marlow in
Google Scholar
PubMed
Search for other papers by John A Copland in
Google Scholar
PubMed
), the potential to integrate a-CGH results with histopathology and other molecular markers, and to relate the laboratory findings with patient diagnosis, prognosis, and therapy, will bring an individualized approach to cancer therapy in clinical practice
Inserm U1016, CNRS UMR 8104, Institut Cochin, Université Paris Descartes-Université de Paris, Paris, France
Search for other papers by Chiara Villa in
Google Scholar
PubMed
Department of Neurosurgery, Hôpital Universitaire Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France
Search for other papers by Bertrand Baussart in
Google Scholar
PubMed
Department of Endocrinology, Center for Rare Adrenal Diseases, Hôpital Cochin APHP, Paris, France
Search for other papers by Guillaume Assié in
Google Scholar
PubMed
Lyon 1 University, Villeurbanne, France
Inserm U1052, CNRS UMR 5286, Cancer Research Center of Lyon, Lyon, France
Search for other papers by Gerald Raverot in
Google Scholar
PubMed
Search for other papers by Federico Roncaroli in
Google Scholar
PubMed
molecular profiling in the classification of PitNETs Considerable progress has been made in the molecular characterisation of PitNETs but unlike other tumour types, the use of molecular markers has not entered diagnostic practice. In this respect, the
Search for other papers by Adriana Albani in
Google Scholar
PubMed
Search for other papers by Luis Gustavo Perez-Rivas in
Google Scholar
PubMed
Search for other papers by Sicheng Tang in
Google Scholar
PubMed
Search for other papers by Julia Simon in
Google Scholar
PubMed
Search for other papers by Kristin Elisabeth Lucia in
Google Scholar
PubMed
Search for other papers by Paula Colón-Bolea in
Google Scholar
PubMed
Search for other papers by Jochen Schopohl in
Google Scholar
PubMed
Search for other papers by Sigrun Roeber in
Google Scholar
PubMed
Search for other papers by Michael Buchfelder in
Google Scholar
PubMed
Search for other papers by Roman Rotermund in
Google Scholar
PubMed
Search for other papers by Jörg Flitsch in
Google Scholar
PubMed
Search for other papers by Jun Thorsteinsdottir in
Google Scholar
PubMed
Search for other papers by Jochen Herms in
Google Scholar
PubMed
Medicover Neuroendocrinology, Munich, Germany
Search for other papers by Günter Stalla in
Google Scholar
PubMed
Search for other papers by Martin Reincke in
Google Scholar
PubMed
Search for other papers by Marily Theodoropoulou in
Google Scholar
PubMed
normalization under pasireotide treatment ( Colao et al. 2012 , Witek et al. 2018 ). Recently, a consensus statement has highlighted the potential of USP8 mutational status as a molecular marker of pasireotide response ( Fleseriu et al. 2021 ). Our
Search for other papers by Simona Falletta in
Google Scholar
PubMed
Search for other papers by Stefano Partelli in
Google Scholar
PubMed
Search for other papers by Corrado Rubini in
Google Scholar
PubMed
Search for other papers by Dominik Nann in
Google Scholar
PubMed
Search for other papers by Andrea Doria in
Google Scholar
PubMed
Search for other papers by Ilaria Marinoni in
Google Scholar
PubMed
Search for other papers by Vanessa Polenta in
Google Scholar
PubMed
Search for other papers by Carmelina Di Pasquale in
Google Scholar
PubMed
Search for other papers by Ettore degli Uberti in
Google Scholar
PubMed
Search for other papers by Aurel Perren in
Google Scholar
PubMed
Search for other papers by Massimo Falconi in
Google Scholar
PubMed
Search for other papers by Maria Chiara Zatelli in
Google Scholar
PubMed
including a very heterogeneous group of NET of different origin. Therefore, the results obtained by Benslama and coworkers may not reflect P-NET behavior ( Benslama et al . 2016 ). Besides putative molecular markers, we also investigated whether P